Teleflex Stock

Teleflex EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Teleflex (TFX) as of Jul 18, 2026 is 8.40. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 8.15 — a change of 3.11% (higher).

EV/EBIT

8.40

YoY

3.11%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Teleflex is 2026 8.40 . EV/EBIT (Enterprise Value to EBIT) of Teleflex was 2025 8.15 . It decreases by 3.11% higher compared to the previous year.

The Teleflex EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
39.99 base
Jan 1, 2020
39.07 base
Jan 1, 2021
27.89 base
Jan 1, 2022
23.00 base
Jan 1, 2023
20.96 base
Jan 1, 2024
15.36 base
Jan 1, 2025 (e)
7.02 base
Jan 1, 2026 (e)
7.23 base
YEARPRICE-TO-EBIT
2026 est 7.23
2025 est 7.02
2024 15.36
2023 20.96
2022 23.00
2021 27.89
2020 39.07
2019 39.99
2018 30.28
2017 29.25
2016 20.49
2015 19.56
2014 17.63
2013 15.10
2012 12.29
2011 10.59
2010 9.31
2009 8.25
2008 7.49
2007 13.42
2006 12.29
2005 14.53
Access this data via the Eulerpool API

Teleflex Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Teleflex's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Teleflex's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Teleflex's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Teleflex grows earnings faster than its peers.

Teleflex Stock analysis

What does Teleflex do? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care. The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors. Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients. In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths. The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources. The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies. With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths. The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators. The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials. The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents. Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Teleflex stock

EV/EBIT (Enterprise Value to EBIT) of Teleflex is 8.40 in 2026.

Access this data via the Eulerpool API

Valuation — Teleflex

All Key Metrics — Teleflex